The only thing this tells me is that ATYR is going to move violently when the Phase 3 Efzofitimod trial data drops this quarter, which is expected sometime after Labor Day. It’s encouraging to see this stock begin to ripen, but it’s also sobering.
Classic Bulls vs Bears setup. Gonna end in tears for someone. Just make damn sure you understand this thing could either rocket above $20 or plummet back to $1!